MedTrace Logo

A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease

NCT00399477 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2011-04-12

No results posted yet for this study

Summary

Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD:

* Group 1 Patients using Azilect and no other therapy.
* Group 2 Azilect in combination with other medications like Levodopa, Mirapex, or Requip.

Conditions

Interventions

DRUG

rasagiline mesylate

Azilect®

DRUG

Rasagiline mesylate plus Mirapex

Mirapex, Azilect®

DRUG

Rasagiline mesylate with Levodopa

Azilect®, Levodopa

DRUG

Rasagiline mesylate with Requip

Azilect®, Requip

Sponsors & Collaborators

  • Teva Neuroscience, Inc.

    lead INDUSTRY

Principal Investigators

  • MerriKay Oleen-Burkey, PhD · Teva Neuroscience, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-10-31
Primary Completion
2007-07-31
Completion
2007-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00399477 on ClinicalTrials.gov